Skip to main
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech Inc. has garnered a positive outlook due to the encouraging results from multiple clinical studies involving its flagship product, Ampligen, particularly in treating various cancers and post-COVID conditions. Recent advancements, including a Phase 2a study demonstrating the efficacy of Ampligen in colorectal cancer and a Phase 2 study for post-COVID patients, provide strong catalysts for potential stock appreciation. The company's focus on pancreatic cancer and its ability to address unmet medical needs further enhance its growth prospects, presenting significant upside opportunities despite inherent risks associated with the biotech sector.

Bears say

AIM ImmunoTech Inc. reported a net loss of $3.3 million for the latest period, translating to an earnings per share (EPS) of $(1.57), which significantly exceeded both internal and consensus estimates. Additionally, the prior period reflected an even higher net loss of $4.2 million with an EPS of $(1.39), also surpassing expected figures. The company faces numerous risks impacting its share price, including liquidity issues, challenges in clinical trial success, regulatory hurdles, commercialization difficulties, and competitive pressures, which collectively suggest a concerning outlook for its financial stability and future growth potential.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Apr 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.